These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
189 related items for PubMed ID: 9817927
1. NF2 gene in neurofibromatosis type 2 patients. Zucman-Rossi J, Legoix P, Der Sarkissian H, Cheret G, Sor F, Bernardi A, Cazes L, Giraud S, Ollagnon E, Lenoir G, Thomas G. Hum Mol Genet; 1998 Dec; 7(13):2095-101. PubMed ID: 9817927 [Abstract] [Full Text] [Related]
2. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain. Koga H, Araki N, Takeshima H, Nishi T, Hirota T, Kimura Y, Nakao M, Saya H. Oncogene; 1998 Aug 20; 17(7):801-10. PubMed ID: 9779996 [Abstract] [Full Text] [Related]
3. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree. MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J. JAMA; 1993 Nov 17; 270(19):2316-20. PubMed ID: 8230593 [Abstract] [Full Text] [Related]
4. [Neurofibromatosis type 2 (NF2)]. Araki N, Takeshima H, Saya H. Gan To Kagaku Ryoho; 1997 Sep 17; 24(11):1427-31. PubMed ID: 9309136 [Abstract] [Full Text] [Related]
5. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Lekanne Deprez RH, Bianchi AB, Groen NA, Seizinger BR, Hagemeijer A, van Drunen E, Bootsma D, Koper JW, Avezaat CJ, Kley N. Am J Hum Genet; 1994 Jun 17; 54(6):1022-9. PubMed ID: 7911002 [Abstract] [Full Text] [Related]
6. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene]. Sabol Z, Kipke-Sabol L, Miklić P, Hajnsek-Propadalo S, Sabol F. Lijec Vjesn; 2006 Jun 17; 128(9-10):309-16. PubMed ID: 17128670 [Abstract] [Full Text] [Related]
7. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Kley N, Whaley J, Seizinger BR. Glia; 1995 Nov 17; 15(3):297-307. PubMed ID: 8586465 [Abstract] [Full Text] [Related]
9. [Development and establishment of a yeast-based stop codon assay for detection of NF2 gene premature-terminating mutations]. Kobayashi H. Hokkaido Igaku Zasshi; 1999 Sep 17; 74(5):377-86. PubMed ID: 10495852 [Abstract] [Full Text] [Related]
10. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Ng HK, Lau KM, Tse JY, Lo KW, Wong JH, Poon WS, Huang DP. Neurosurgery; 1995 Oct 17; 37(4):764-73. PubMed ID: 8559307 [Abstract] [Full Text] [Related]
11. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Bruder CE, Hirvelä C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, Zucman-Rossi J, Hergersberg M, Boltshauser E, Papi L, Rouleau GA, Poptodorov G, Jordanova A, Rask-Andersen H, Kluwe L, Mautner V, Sainio M, Hung G, Mathiesen T, Möller C, Pulst SM, Harder H, Heiberg A, Honda M, Niimura M, Sahlén S, Blennow E, Albertson DG, Pinkel D, Dumanski JP. Hum Mol Genet; 2001 Feb 01; 10(3):271-82. PubMed ID: 11159946 [Abstract] [Full Text] [Related]
12. Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction. Diebold R, Bartelt-Kirbach B, Evans DG, Kaufmann D, Hanemann CO. J Mol Diagn; 2005 Feb 01; 7(1):97-104. PubMed ID: 15681480 [Abstract] [Full Text] [Related]
13. Molecular characterization of germline NF2 gene rearrangements. Legoix P, Sarkissian HD, Cazes L, Giraud S, Sor F, Rouleau GA, Lenoir G, Thomas G, Zucman-Rossi J. Genomics; 2000 Apr 01; 65(1):62-6. PubMed ID: 10777666 [Abstract] [Full Text] [Related]
14. NF2: the wizardry of merlin. Xiao GH, Chernoff J, Testa JR. Genes Chromosomes Cancer; 2003 Dec 01; 38(4):389-99. PubMed ID: 14566860 [Abstract] [Full Text] [Related]
15. Expression of neurofibromatosis 2 transcript and gene product during mouse fetal development. Huynh DP, Tran TM, Nechiporuk T, Pulst SM. Cell Growth Differ; 1996 Nov 01; 7(11):1551-61. PubMed ID: 8930405 [Abstract] [Full Text] [Related]
16. Mutational analysis of patients with neurofibromatosis 2. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K, Trofatter JA, Short MP, Bove C, Eldridge R. Am J Hum Genet; 1994 Aug 01; 55(2):314-20. PubMed ID: 7913580 [Abstract] [Full Text] [Related]
17. CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor. MacCollin M. Brain Dev; 1995 Aug 01; 17(4):231-8. PubMed ID: 7503383 [Abstract] [Full Text] [Related]
18. Characterisation of 16 polymorphic markers in the NF2 gene: application to hemizygosity detection. Legoix P, Legrand MF, Ollagnon E, Lenoir G, Thomas G, Zucman-Rossi J. Hum Mutat; 1999 Aug 01; 13(4):290-3. PubMed ID: 10220142 [Abstract] [Full Text] [Related]
19. Neurofibromatosis type 2: a new mechanism of tumor suppression. Lutchman M, Rouleau GA. Trends Neurosci; 1996 Sep 01; 19(9):373-7. PubMed ID: 8873351 [Abstract] [Full Text] [Related]
20. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA. Am J Hum Genet; 1996 Aug 01; 59(2):331-42. PubMed ID: 8755919 [Abstract] [Full Text] [Related] Page: [Next] [New Search]